[Disclosure] Celltrion (068270) – Execution of License-in Agreement for Microbiome Gut Disease Drug Candidates / 2026-03-25
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has entered into a global exclusive license-in agreement with KOBIOLABS, Inc. (worth up to KRW 205.2B) for three microbiome candidate strains targeting irritable bowel syndrome with diarrhea (IBS-d) and functional health foods. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint)…